DreaMed Diabetes Deploys AI Technology, the First-of-Its-Kind in Telemedicine

More than a million Americans are living with type 1 diabetes, and according to the American Diabetes Association, an estimated 40,000 people who are living in the United States are receiving type 1 diagnosis each year. Because of the large population in the United States, the healthcare system is suffering under the weight of so many people diagnosed with this disease. The recent pandemic, urgent solutions, and initiatives are needed to address this growing concern.

DreaMed Diabetes Ltd. is the developer of personalized, AI-based diabetes management solutions. They have announced their expansion across the U.S. through partnering with various health clinics, which includes Lucile Packard Children's Hospital Stanford, the Billings Clinic in Montana, Hassenfeld Children's Hospital at NYU Langone, and UF Health. Through this partnership, patients across the country, especially those residing in rural areas, can now have access to a more personalized treatment from the comforts of their own home.

FURTHER READING: DreaMed to Participate in $5Million Study for Virtual Healthcare for Diabetic Patients

The clinics involved will be implementing the DreaMed's diabetes protocol, DreaMed Advisor Pro software. This is a cloud-based remote insulin management technology that utilizes artificial intelligence for swift data analysis and speedy treatment. Patients will receive a personalized optimization of their insulin therapy management with recommendations coming from the information analyzed from CGM, glucometers, insulin pumps, and the use of event-oriented data.

Insulin Dose Optimization

Despite the advancement in science and technology, diabetes remains an incurable life-long disease. Most people with type 1 diabetes are not able to reach their glycemic goals, which may be due to the lack of expertise or an insufficient amount of time for clinicians to analyze complex sensor-augmented pump data.  

U.S. diabetics clinics employed this AI-based decision-support technology, via telemedicine, to manage insulin therapy among people with diabetes. This is the first-of-its-kind FDA cleared applications of AI and telehealth.

The primary research finding for this automated AI system is that it can be as useful in administering frequent insulin adjustments remotely as than of an expert physician making dose adjustments.

The use of AI allows a continuous and burden-free remote monitoring of the symptoms and biomarkers of a patient. This will create a paradigm shift in diabetes care, from the more conventional management strategies to a highly targeted data-driven precision care.

DreaMed Advisor  

DreaMed Advisor is a real-time personalized medicine and decision-support tool that can quickly and automatically determine the optimal treatment for maintaining a patient's glucose levels. It is powered by the MD Logic algorithm and charged by artificial intelligence. Designed to emulate how expert endocrinologists evaluate their patients, this AI will provide faster and more refined analysis and insights.

MD Logic utilizes all available real-world data on insulin dosing and blood glucose such as sensor readings, fingerstick measurements, meal or carb intake data), including patient reporting to achieve maximum accuracy and a complete picture.

DreaMed is now focused on the commercialization of Advisor Pro for the advancement of endocrinology towards the future of telemedicine. By providing remote, frequent treatments, more people with diabetes can now access better care.

MORE ABOUT: New COVID-19 Laws That Government Announced Quietly at Midnight Spark Backlash 

Check out more news and information on Diabetes on MD News Daily.  

© MD News Daily.